Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $44.41 USD
Change Today -0.57 / -1.27%
Volume 487.1K
THOR On Other Exchanges
As of 8:10 PM 06/29/15 All times are local (Market data is delayed by at least 15 minutes).

thoratec corp (THOR) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/22/15 - $46.50
52 Week Low
08/7/14 - $22.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for THORATEC CORP (THOR)

thoratec corp (THOR) Related Businessweek News

No Related Businessweek News Found

thoratec corp (THOR) Details

Thoratec Corporation, together with its subsidiaries, develops, manufactures, and markets proprietary medical devices used for mechanical circulatory support for the treatment of heart failure patients. The company’s primary product lines include ventricular assist devices, including HeartMate II, an implantable, electrically powered, continuous flow, left ventricular assist device (LVAD) consisting of a rotary blood pump designed to provide intermediate and long-term mechanical circulatory support (MCS); CentriMag an extracorporeal circulatory support device that provides hemodynamic stabilization in patients in need of cardiopulmonary support. It also offers PediMag and PediVAS extracorporeal full-flow acute surgical support platforms incorporating a polycarbonate pump, based on magnetically levitated bearingless motor technology, designed to provide acute surgical support to pediatric patients. In addition, it provides Thoratec Paracorporeal Ventricular Assist Device (PVAD) an external, pulsatile ventricular assist device (VAD), FDA-approved for bridge-to-transplantation (BTT) and post-cardiotomy myocardial recovery; and Thoratec Implantable Ventricular Assist Device (IVAD) an implantable, pulsatile, VAD, FDA-approved for BTT, including home discharge, and post-cardiotomy myocardial recovery and provides left, right or biventricular MCS The company markets its products through cardiovascular sales specialists and distributors in the United States and internationally. Thoratec Corporation was founded in 1976 and is headquartered in Pleasanton, California.

954 Employees
Last Reported Date: 02/19/15
Founded in 1976

thoratec corp (THOR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $201.9K
Chief Financial Officer and Vice President
Total Annual Compensation: $341.3K
President of North America
Total Annual Compensation: $233.1K
Senior Vice President and General Counsel
Total Annual Compensation: $355.8K
Senior Vice President of Technical Operations
Total Annual Compensation: $190.7K
Compensation as of Fiscal Year 2014.

thoratec corp (THOR) Key Developments

Thoratec Corporation Receives Conditional FDA Approval for the Shield II U.S. Clinical Trial for Heartmate PHP

Thoratec Corporation announced that the FDA has granted conditional approval for a U.S. IDE clinical trial to investigate use of the HeartMate PHP acute catheter-based heart pump in patients undergoing a high-risk percutaneous coronary intervention. The SHIELD II (Supporting patients undergoing HIgh-risk PCI using a high-flow pErcutaneous Left ventricular support Device) U.S. clinical trial will randomize up to 425 patients at up to 60 sites against the Impella® 2.5 at a 2:1 ratio. Individual sites may immediately begin randomization after performing a series of up to three HeartMate PHP procedures for purposes of training and familiarity. The primary endpoint will measure non-inferiority based on a composite of adverse events at 90 days of follow-up. Final FDA approval is expected in the coming months pending resolution of certain routine technical questions. HeartMate PHP is an acute cardiac assist device designed to disrupt the traditional relationship between size and flow in catheter-based support devices. The proprietary expandable catheter technology of HeartMate PHP is capable of generating average blood flow of four to five liters per minute following delivery through a true percutaneous insertion. The device has also been designed for hemocompatibility, with operating RPMs of 17,000-20,000.

Thoratec Corp. Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-09-2015 02:00 PM

Thoratec Corp. Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-09-2015 02:00 PM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States. Speakers: D. Keith Grossman, Chief Executive Officer, President and Director.

Thoratec Corp. Report Unaudited Consolidated Earnings Results for the First Quarter Ended April 4, 2015; Revised Earnings Guidance for Fiscal 2015

Thoratec Corp. reported unaudited consolidated earnings results for the first quarter ended April 4, 2015. For the quarter ended April 4, 2015, Thoratec reported revenues of $121.3 million, a 4% decrease versus revenues of $125.7 million in the same period a year ago. Revenues for the period increased 4% compared with the prior year excluding changes in foreign exchange and results in Japan, where unusual order patterns impact reported growth. Income from operations was $17.9 million against $26.8 million last year. Income before taxes was $18.8 million against $27.1 million last year. GAAP net income was $10.8 million, or $0.20 per basic and diluted share, compared to GAAP net income of $18.2 million, or $0.32 per basic and diluted share, in the same period last year. Non-GAAP net income was $20.9 million, or $0.38 per diluted share, in the first quarter of 2015, compared to non-GAAP net income of $23.7 million, or $0.41 per diluted share, in the first quarter of 2014. The company expects fiscal 2015 revenues to be in a range of $465 million to $475 million, an increase of $15 million over initial 2015 guidance. This new range incorporates first quarter performance and a modestly improved outlook for the full year market growth, which it now believes will be in the mid-single digits for 2015. Incorporated into this guidance range are the negative impacts of foreign exchange movements and having one fewer week in fiscal 2015 relative to fiscal 2014, the combined effect of which is approximately $23 million, an increase of $5 million from previous guidance due to additional unfavorable movement in foreign exchange rates. Guidance for net income per diluted share is a range of $0.58 to $0.68 on a GAAP basis and the company raised non-GAAP EPS guidance to a range of $1.15 to $1.25. The company expects the effective tax rate to be approximately 33.5% on a GAAP basis and approximately 30.0% on a non-GAAP basis.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
THOR:US $44.41 USD -0.57

THOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ABIOMED Inc $65.33 USD -1.42
ICU Medical Inc $94.79 USD -1.01
Masimo Corp $38.55 USD -0.91
Merit Medical Systems Inc $21.12 USD -0.41
NuVasive Inc $47.60 USD -1.42
View Industry Companies

Industry Analysis


Industry Average

Valuation THOR Industry Range
Price/Earnings 58.7x
Price/Sales 5.1x
Price/Book 3.8x
Price/Cash Flow 56.8x
TEV/Sales 4.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THORATEC CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at